JuneBrain

JuneBrain

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://junebrain.com

Last Round

Grant

Oct 30, 2025

Est. Valuation

$8M

Total Funding Raised

$1.93M

Company Overview

JuneBrain is a medical device company that develops a wearable retinal imaging system and AI software to optimize remote assessment and monitoring of neurological and retinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging, Medical AI, Telemedicine, Clinical Trials

Business Model

B2B

Customer Profile

Hardware + Subscription, Subscription SaaS, Government Contracts, Hardware Sales

AI Layer

Application

Keywords

optical coherence tomographyOCTportable OCTretinal imagingremote patient monitoringtelehealthmedtechmedical AIwearable eye scannerneurological monitoringAI medical imaging analysismedical deviceclinical trial technologypoint-of-care testingmultiple sclerosismacular degenerationhardware and SaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

JuneBrain Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

JuneBrain Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantOct 30, 2025
Pre SeedOct 9, 2025
Pre SeedSep 10, 2024
GrantSep 9, 2024
CrowdfundingMar 4, 2023
Grant
Mar 3, 2023

Key People

Founding team and executive leadership

Samantha Scott

Founder And CEO

Founding Team

JuneBrain Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 17, 2026

    Partnering with Tulane University for telehealth research.

  • Nov 10, 2025

    Participated in the 2025 BioChallenge Pitch Competition.

JuneBrain Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

JuneBrain Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about JuneBrain's valuation, stock price, and market status.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range15
Year Founded2017
Last FundingOct 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.